FN2 Earnings Intelligence
BridgeBio Pharma, Inc. income statement
BridgeBio Pharma, Inc. (BBIO) Income Statement (annual) derived from persisted SEC financial facts.
Key Stats
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 | 12/31/2026 est. | 12/31/2027 est. |
|---|---|---|---|---|---|---|---|
| Market Cap | - | - | - | - | - | - | - |
| - Cash | $393.8 | $376.7 | $375.9 | $681.1 | $570.1 | - | - |
| + Debt | - | - | - | - | - | - | - |
| Enterprise Value | - | - | - | - | - | - | - |
| Revenue | $69.7 | $77.6 | $9.3 | $221.9 | $502.1 | $1,020.3 | $1,680.8 |
| % Growth | 745.1% | 11.4% | -88.0% | 2,285.3% | 126.3% | 103.2% | 64.7% |
| Gross Profit | $67 | - | $6.9 | $218 | $481.1 | - | - |
| % Margin | 96.1% | - | 73.7% | 98.3% | 95.8% | - | - |
| EBITDA | -$570.8 | -$505.4 | -$600.9 | -$586.9 | -$518 | - | - |
| % Margin | -818.7% | -650.9% | -6,458.9% | -264.5% | -103.2% | - | - |
| Net Income | -$586.5 | -$484.7 | -$653.3 | -$543.3 | -$732.9 | - | - |
| % Margin | -841.2% | -624.2% | -7,021.9% | -244.9% | -146.0% | - | - |
| Diluted EPS | - | -$3.26 | -$3.95 | -$2.88 | -$3.78 | -$2.78 | $0.08 |
| % Growth | - | - | -21.2% | 27.1% | -31.2% | 26.4% | 103.0% |
| Operating Cash Flow | -$497.9 | -$419.5 | -$527.7 | -$520.7 | -$445.9 | - | - |
| CapEx | $13.2 | $4.8 | $1.3 | $0.9 | $1.1 | - | - |
| Free Cash Flow | -$511.2 | -$424.3 | -$529 | -$521.7 | -$447 | - | - |
Historical market capitalization is not persisted, so Market Cap and Enterprise Value remain unavailable rather than mixing today's market value into prior periods.
Income Statement
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 | 12/31/2026 est. | 12/31/2027 est. |
|---|---|---|---|---|---|---|---|
| Revenue | $69.7 | $77.6 | $9.3 | $221.9 | $502.1 | $1,020.3 | $1,680.8 |
| Gross Profit | $67 | - | $6.9 | $218 | $481.1 | - | - |
| EBITDA | -$570.8 | -$505.4 | -$600.9 | -$586.9 | -$518 | - | - |
| Net Income | -$586.5 | -$484.7 | -$653.3 | -$543.3 | -$732.9 | - | - |
| Diluted EPS | - | -$3.26 | -$3.95 | -$2.88 | -$3.78 | -$2.78 | $0.08 |
Balance Sheet
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $393.8 | $376.7 | $375.9 | $681.1 | $570.1 |
| Short-term Debt | - | - | - | - | - |
| Long-term Debt | $430.8 | $431 | $446.4 | $437.3 | $2,007.3 |
| Total Debt | - | - | - | - | - |
Cash Flow
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$497.9 | -$419.5 | -$527.7 | -$520.7 | -$445.9 |
| Capital Expenditure | $13.2 | $4.8 | $1.3 | $0.9 | $1.1 |
| Free Cash Flow | -$511.2 | -$424.3 | -$529 | -$521.7 | -$447 |
Ratios
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Revenue Growth | 745.1% | 11.4% | -88.0% | 2,285.3% | 126.3% |
| Gross Margin | 96.1% | - | 73.7% | 98.3% | 95.8% |
| EBITDA Margin | -818.7% | -650.9% | -6,458.9% | -264.5% | -103.2% |
| Net Margin | -841.2% | -624.2% | -7,021.9% | -244.9% | -146.0% |
| FCF Margin | -733.2% | -546.5% | -5,686.6% | -235.1% | -89.0% |
| Diluted EPS Growth | - | - | -21.2% | 27.1% | -31.2% |
Get the BBIO recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.